Skip to main content

Advertisement

Fig. 1 | Molecular Cancer

Fig. 1

From: MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer

Fig. 1

Prognostic value of miR-30d expression in PCa patients and its functions on tumor growth and angiogenesis in vivo using LNCaP cell induced tumor xenografts. a Kaplan-Meier analyses of biochemical recurrence (BCR)-free survival and overall survival of PCa patients based on miR-30d expression in Taylor and TCGA datasets. b LNCaP cells stably expressing miR-30d formed significantly larger tumor nodules and remarkably speeded up tumor xenografts growth compared with the controls. Conversely, PCa cells that permanently suppressed miR-30d expression led to the smaller tumor nodules and the slower tumor growth compared with the control. c Immunohistochemical analysis using pan-endothelial marker CD31 antibody. d VEGFA protein expression in different groups detected by Western blot analysis. Data were presented as Mean ± SD. *P < 0.05. **P < 0.01

Back to article page